L K Stamp

Summary

Country: New Zealand

Publications

  1. ncbi Gout and its comorbidities: implications for therapy
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 52:34-44. 2013
  2. ncbi Myeloperoxidase and oxidative stress in rheumatoid arthritis
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 51:1796-803. 2012
  3. ncbi Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, 2 Riccarton Ave, Christchurch 8014, New Zealand
    Arthritis Res Ther 14:R138. 2012
  4. ncbi Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 51:1670-6. 2012
  5. ncbi Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 64:2529-36. 2012
  6. ncbi The Christchurch earthquake--providing a rheumatology service during a natural disaster
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, Christchurch 8104, New Zealand
    Clin Rheumatol 31:723-5. 2012
  7. ncbi Gout and organ transplantation
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, P O Box 4345, Christchurch, 8140, New Zealand
    Curr Rheumatol Rep 14:165-72. 2012
  8. ncbi The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9012, New Zealand
    Arthritis Res Ther 13:R85. 2011
  9. ncbi The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9054, New Zealand
    Arthritis Res Ther 11:R152. 2009
  10. ncbi Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    J Rheumatol 38:2540-7. 2011

Collaborators

Detail Information

Publications45

  1. ncbi Gout and its comorbidities: implications for therapy
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 52:34-44. 2013
    ..This review will consider the relationship between comorbidities and gout with a particular focus on the treatment of gout and the potential interactions between drugs used for gout and those for comorbid conditions...
  2. ncbi Myeloperoxidase and oxidative stress in rheumatoid arthritis
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 51:1796-803. 2012
    ..To determine whether MPO contributes to oxidative stress and disease activity in RA and whether it produces hypochlorous acid in SF...
  3. ncbi Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, 2 Riccarton Ave, Christchurch 8014, New Zealand
    Arthritis Res Ther 14:R138. 2012
    ..Furthermore, we investigated whether polymorphisms within ADORA3 were associated with response and/or adverse effects associated with MTX...
  4. ncbi Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch 8140, New Zealand
    Rheumatology (Oxford) 51:1670-6. 2012
    ..To determine the effects of furosemide on serum urate (SU), plasma oxypurinol and urinary urate...
  5. ncbi Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 64:2529-36. 2012
    ..However, the relationship between the allopurinol starting dose and AHS is unknown. This study was undertaken to determine the relationship between allopurinol dosing and AHS...
  6. ncbi The Christchurch earthquake--providing a rheumatology service during a natural disaster
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, Christchurch 8104, New Zealand
    Clin Rheumatol 31:723-5. 2012
    ....
  7. ncbi Gout and organ transplantation
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, P O Box 4345, Christchurch, 8140, New Zealand
    Curr Rheumatol Rep 14:165-72. 2012
    ..Other options include febuxostat and benzbromarone. The role of newer agents such as interleukin-1 inhibitors and uricases remains to be determined. General measures should include minimizing diuretic use...
  8. ncbi The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severity
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9012, New Zealand
    Arthritis Res Ther 13:R85. 2011
    ..There is no evidence for an association with gout in Caucasian populations. In the present study, we tested rs3733591 for association with gout in New Zealand (NZ) Māori, Pacific Island and Caucasian samples...
  9. ncbi The ITGAV rs3738919 variant and susceptibility to rheumatoid arthritis in four Caucasian sample sets
    Jade E Hollis-Moffatt
    Department of Biochemistry, University of Otago, 710 Cumberland Street, Dunedin 9054, New Zealand
    Arthritis Res Ther 11:R152. 2009
    ..We therefore tested this association in an independent study using New Zealand (NZ) and Oxford (UK) RA case control samples...
  10. ncbi Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    J Rheumatol 38:2540-7. 2011
    ..To determine the effects of changing from oral to subcutaneous (SC) methotrexate (MTX) in patients with rheumatoid arthritis (RA) on red blood cell MTX polyglutamate (RBC MTXGlu(n)) concentrations, disease activity, and adverse effects...
  11. ncbi Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Pharmacogenet Genomics 20:367-76. 2010
    ..To determine whether genetic polymorphisms within the folate pathway are associated with red blood cell (RBC) methotrexate (MTX) polyglutamate concentrations, RBC folate concentrations and MTX efficacy/toxicity...
  12. ncbi Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 62:359-68. 2010
    ....
  13. ncbi Diet and rheumatoid arthritis: a review of the literature
    Lisa K Stamp
    Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
    Semin Arthritis Rheum 35:77-94. 2005
    ..A large number of patients seek alternative or complementary therapies of which diet is an important component. This article reviews the evidence for diet in rheumatoid arthritis along with the associated concept of oral tolerization...
  14. ncbi Serum urate as a soluble biomarker in chronic gout-evidence that serum urate fulfills the OMERACT validation criteria for soluble biomarkers
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Semin Arthritis Rheum 40:483-500. 2011
    ..To determine whether serum urate (SU) fulfills the Outcome measures in Rheumatology (OMERACT) soluble biomarker criteria...
  15. ncbi Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 63:412-21. 2011
    ..To determine the efficacy and safety of increasing the allopurinol dose above the proposed creatinine clearance-based dose in patients with gout...
  16. ncbi Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    J Rheumatol 38:1462-6. 2011
    ..To summarize evidence for and endorsement of serum urate (SU) as having fulfilled the OMERACT filter as a soluble biomarker in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10)...
  17. ncbi Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level
    L K Stamp
    Department of Medicine, University of Otago, Christchurch, New Zealand
    Clin Pharmacol Ther 90:392-8. 2011
    ..2 mg/l). Increasing the allopurinol dose resulted in increased plasma oxypurinol and reduced SU concentrations. Plasma oxypurinol concentrations >100 µmol/l were required to achieve SU <6 mg/dl...
  18. ncbi The challenges of gout management in the elderly
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Drugs Aging 28:591-603. 2011
    ..Careful consideration of the patient's concomitant medications is required as many drugs increase serum urate. Successful urate lowering will ultimately reduce gout flares and thereby improve patient quality of life...
  19. ncbi Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases
    Lisa K Stamp
    Department of Biochemistry, University of Otago, Dunedin 9054, New Zealand
    Pharmacogenomics 12:1449-63. 2011
    ..Prospective studies, standardizing the definitions of response and toxicity, and application of genome-wide approaches may advance the search for genetic predictors of MTX response...
  20. ncbi Monocyte derived interleukin (IL)-23 is an important determinant of synovial IL-17A expression in rheumatoid arthritis
    Lisa K Stamp
    Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand
    J Rheumatol 36:2403-8. 2009
    ..To demonstrate gene expression of interleukin (IL)-17A, IL-23, and IL-12 and to determine the proximity of IL-17A and IL-23 producing cells in rheumatoid synovial tissue...
  21. ncbi Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment
    Lisa K Stamp
    Department of Mediicne, University of Otago, Christchurch, New Zealand
    Arthritis Rheum 60:2248-56. 2009
    ..This study was undertaken to determine nongenetic factors that influence red blood cell (RBC) MTXGlun concentrations in patients receiving long-term stable low-dose oral MTX...
  22. ncbi The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?
    Lisa Stamp
    Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, P O Box 4345, Christchurch, New Zealand
    Biomed Pharmacother 60:678-87. 2006
    ..Although in their infancy at present, both therapeutic drug monitoring using MTXPG concentrations and pharmacogenomics of MTX may prove useful in the future and are worthy of further investigation...
  23. ncbi Different T cell subsets in the nodule and synovial membrane: absence of interleukin-17A in rheumatoid nodules
    Lisa K Stamp
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 58:1601-8. 2008
    ..To determine gene expression of the interleukin-17 (IL-17) family members (IL-17A-F) in rheumatoid subcutaneous nodules, and to assess the cytokines involved in regulating IL-17A expression...
  24. ncbi HLA-B27 associated spondyloarthropathy, vasculitis, and amyloid enteropathy: response to infliximab
    Lisa K Stamp
    Department of Medicine and Health Sciences, Christchurch School of Medicine, Otago University, Christchurch, New Zealand
    J Rheumatol 32:382-5. 2005
    ..Treatment with infliximab resulted in resolution of joint symptoms and rapid improvement in laboratory markers of inflammation. Diarrhea settled more gradually, such that her bowel habit had normalized 16 months after therapy commenced...
  25. ncbi Gout in solid organ transplantation: a challenging clinical problem
    Lisa Stamp
    Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    Drugs 65:2593-611. 2005
    ..Recognition and, if possible, alleviation of risk factors, prompt treatment of acute attacks and early introduction of hypouricaemic therapy with careful monitoring are the keys to successful management...
  26. ncbi Gout in renal transplant recipients
    Lisa Stamp
    Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand
    Nephrology (Carlton) 11:367-71. 2006
    ..In addition, the authors wished to assess the impact of post-renal transplant gout on the patient...
  27. ncbi Emerging therapies in the long-term management of hyperuricaemia and gout
    L K Stamp
    Department of Medicine, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
    Intern Med J 37:258-66. 2007
    ....
  28. ncbi Evidence for association of an interleukin 23 receptor variant independent of the R381Q variant with rheumatoid arthritis
    J E Hollis-Moffatt
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Ann Rheum Dis 68:1340-4. 2009
    ..While there is no previous support for strong association of IL23R with RA, the possibility of a weaker role for IL23R variants in the aetiology of RA cannot be eliminated...
  29. ncbi Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis
    D H N White
    Department of Rheumatology, Immunology and Allergy, Canterbury District Health Board, Christchurch, New Zealand
    Intern Med J 40:561-5. 2010
    ..We wished to identify whether there was an association between MCV, red cell folate and haematological toxicity in patients on MTX monotherapy for the long-term management of RA...
  30. ncbi Soluble human leukocyte antigen: a diagnostic indicator of rheumatoid arthritis?
    M W Hayman
    Immunology Section, Canterbury Health Laboratories, Christchurch, New Zealand
    J Immunol Methods 315:19-26. 2006
    ..In RA patients, we detected high levels of sHLA-DR in aspirated synovial fluid (SF), but this did not correlate with sHLA-DR levels in serum...
  31. ncbi Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient
    J L O'Donnell
    Department of Rheumatology, Immunology and Allergy, Canterbury Health Laboratories, Christchurch 8001, New Zealand
    Intern Med J 37:242-6. 2007
    ..The aim of the study was to determine whether there was evidence for a geographic gradient in the incidence of Wegener's granulomatosis (WG) and WG-like disease in New Zealand (NZ)...
  32. ncbi Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis
    Judith M Dalrymple
    University of Otago, Christchurch, New Zealand
    Arthritis Rheum 58:3299-308. 2008
    ....
  33. ncbi Antineutrophil cytoplasmic antibody measurement: advantages and disadvantages of a capture PR3 ELISA and a direct PR3 ELISA
    John L O'Donnell
    Department of Rheumatology, Immunology and Allergy, Canterbury Health Laboratories, Canterbury District Health Board, Christchurch, New Zealand
    Pathology 39:258-63. 2007
    ..To compare the performance of a capture proteinase 3 enzyme linked immunosorbent assay (PR3 ELISA) with a direct PR3 ELISA in the measurement of PR3 antineutrophil cytoplasmic antibodies (ANCA)...
  34. ncbi IL-23R rs11209026 polymorphism modulates IL-17A expression in patients with rheumatoid arthritis
    J Hazlett
    Leukocyte Inflammation Research Laboratory, Department of Physiology, University of Otago, Dunedin, New Zealand
    Genes Immun 13:282-7. 2012
    ..This suggests altered IL-23R function in patients with the minor allele and warrants further functional studies...
  35. ncbi Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis
    C McKinney
    Department of Biochemistry, University of Otago, PO Box 56, Dunedin, New Zealand
    Ann Rheum Dis 67:409-13. 2008
    ....
  36. ncbi Wegener's granulomatosis: treatment and survival characteristics in a high-prevalence southern hemisphere region
    A R Khan
    Department of Rheumatology, Immunology and Allergy, Canterbury District Health Board, Christchurch, New Zealand
    Intern Med J 42:e23-6. 2012
    ..Survivorship, treatment response rate and the rate of relapse from WG in a cohort of patients from this high-prevalence southern hemisphere region were similar to that reported for northern hemisphere cohorts with a similar prevalence...
  37. ncbi The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region
    A Gibson
    Department of Rheumatology, Immunology and Allergy, Canterbury District Health Board, University of Otago, Christchurch, New Zealand
    Rheumatology (Oxford) 45:624-8. 2006
    ..Studies of disease prevalence in other Southern Hemisphere centres will determine if the observed north-south negative disease gradient in the Northern Hemisphere is reciprocated...
  38. ncbi Leflunomide-associated infections in rheumatoid arthritis
    Katey A Jenks
    Department of Rheumatology, Immunology and Allergy, Christchurch Hospital, Christchurch, New Zealand
    J Rheumatol 34:2201-3. 2007
    ..To determine the prevalence of severe infections in patients with rheumatoid arthritis (RA) prescribed leflunomide in North Canterbury, New Zealand...
  39. ncbi Association of variation in Fcgamma receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples
    Cushla McKinney
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    Ann Rheum Dis 69:1711-6. 2010
    ....
  40. ncbi Only one independent genetic association with rheumatoid arthritis within the KIAA1109-TENR-IL2-IL21 locus in Caucasian sample sets: confirmation of association of rs6822844 with rheumatoid arthritis at a genome-wide level of significance
    Jade E Hollis-Moffatt
    Department of Biochemistry, 710 Cumberland Street, University of Otago, Dunedin 9054, New Zealand
    Arthritis Res Ther 12:R116. 2010
    ..Here we aimed to: one, confirm at a genome-wide level of significance association of rs6822844 with RA and, two, evaluate whether or not there were effects independent of rs6822844 on RA at the KIAA1109-TENR-IL2-IL21 locus...
  41. ncbi Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use
    Susanna M Proudman
    Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia
    Semin Arthritis Rheum 37:99-111. 2007
    ..To assess the safety and efficacy of combination therapy in recent-onset rheumatoid arthritis (RA), with dose adjustments determined by response, in a clinic setting over 3 years...
  42. ncbi A biomarker of n-3 compliance in patients taking fish oil for rheumatoid arthritis
    Leslie G Cleland
    Rheumatology Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia
    Lipids 38:419-24. 2003
    ..It may also provide a guide to the effectiveness of therapeutic and preventive messages designed to increase n-3 PUFA intake...
  43. ncbi Paracrine upregulation of monocyte cyclooxygenase-2 by mediators produced by T lymphocytes: role of interleukin 17 and interferon-gamma
    Lisa K Stamp
    Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide SA 5000, Australia
    J Rheumatol 31:1255-64. 2004
    ..In rheumatoid joints, previously observed high concentrations of IL-17 and low concentrations of IFN-g could contribute to T cell-driven upregulation of monocyte COX-2...
  44. ncbi Upregulation of synoviocyte COX-2 through interactions with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha
    Lisa K Stamp
    Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide SA 5000, Australia
    J Rheumatol 31:1246-54. 2004
    ..These data provide additional evidence for the contribution of T cells in rheumatoid inflammation and highlight the potential of IL-17 as a therapeutic target...
  45. ncbi Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis?
    Lisa K Stamp
    Rheumatology Unit, Eleanor Harrald Building, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia
    Immunol Cell Biol 82:1-9. 2004
    ..As such, IL-17 warrants consideration for its potential as a therapeutic target in rheumatoid arthritis...